Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The group is persevering with Granite, but funds might be hard to come by.
First-in-human trial initiations reveal four KRAS assets.
For $850m up front Roche gets to challenge Pfizer.
